Latest Ratios: P/E Ratio 8.4x · EV/EBITDA 7.4x · ROE N/A. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.1B | $1.7B | $1.6B | $1.2B | $2.1B | $2.5B | $1.2B | $399M | $833M | $415M | $467M |
| Enterprise Value | $2.5B | $2.1B | $2.3B | $1.9B | $2.6B | $2.6B | $1.3B | $369M | $868M | $419M | $498M |
| P/E Ratio → | 8.40 | 6.45 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 2.44 | 1.95 | 3.45 | 3.47 | 7.88 | 15.78 | 69.96 | 8.17 | 40.32 | 16.46 | 17.70 |
| P/B Ratio | — | — | — | — | — | — | — | 10.43 | — | — | — |
| P/FCF | 6.52 | 5.21 | — | — | — | — | — | — | — | — | — |
| P/OCF | 6.47 | 5.17 | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.39 | 5.08 | 5.63 | 9.49 | 16.35 | 70.37 | 7.56 | 42.02 | 16.64 | 18.90 |
| EV / EBITDA | 7.37 | 6.11 | — | — | — | — | — | — | — | — | — |
| EV / EBIT | 7.40 | 6.04 | 198.14 | — | — | — | — | — | — | — | — |
| EV / FCF | — | 6.39 | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 97.8% | 97.8% | 97.2% | 98.6% | 97.6% | 95.4% | 90.6% | 91.6% | 97.7% | 93.2% | 89.8% |
| Operating Margin | 39.0% | 39.0% | -0.6% | -31.3% | -54.8% | -113.1% | -981.1% | -203.7% | -456.2% | -227.9% | -184.4% |
| Net Profit Margin | 30.2% | 30.2% | -19.7% | -68.4% | -91.2% | -117.1% | -1026.4% | -223.0% | -490.3% | -261.2% | -209.3% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | -1925.4% | -284.7% | — | — | — |
| ROA | 52.5% | 52.5% | -17.6% | -42.5% | -43.4% | -39.9% | -71.7% | -67.6% | -62.3% | -49.1% | -51.4% |
| ROIC | 96.7% | 96.7% | -0.7% | -38.8% | -179.6% | — | — | — | — | — | — |
| ROCE | 105.2% | 105.2% | -0.7% | -25.6% | -32.0% | -49.8% | -112.0% | -124.1% | -104.2% | -82.7% | -101.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | 2.21 | — | — | — |
| Debt / EBITDA | 1.39 | 1.39 | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | — | — | — | -0.77 | — | — | — |
| Net Debt / EBITDA | 1.13 | 1.13 | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | 1.18 | — | — | — | — | — | — | — | — | — |
| Interest Coverage | 4.39 | 4.39 | 0.12 | -1.09 | -1.47 | -2.07 | -11.61 | -8.16 | -10.03 | -6.68 | -7.50 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.06 | 2.06 | 2.63 | 3.31 | 4.90 | 5.46 | 3.06 | 1.78 | 1.65 | 1.68 | 1.23 |
| Quick Ratio | 2.03 | 2.03 | 2.58 | 3.12 | 4.63 | 5.31 | 3.00 | 1.78 | 1.62 | 2.18 | 1.22 |
| Cash Ratio | 1.40 | 1.40 | 2.00 | 2.59 | 4.02 | 4.89 | 2.84 | 1.48 | 1.50 | 1.53 | 1.01 |
| Asset Turnover | — | 1.70 | 0.92 | 0.64 | 0.49 | 0.27 | 0.05 | 0.28 | 0.14 | 0.14 | 0.29 |
| Inventory Turnover | 3.53 | 3.53 | 1.54 | 0.16 | 0.24 | 0.46 | 0.24 | — | 0.29 | — | 5.40 |
| Days Sales Outstanding | — | 44.57 | 64.03 | 62.72 | 68.19 | 68.31 | 177.17 | 165.52 | 75.87 | 88.65 | 121.44 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 11.9% | 15.5% | — | — | — | — | — | — | — | — | — |
| FCF Yield | 15.3% | 19.2% | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $219M | $207M | $192M | $186M | $179M | $167M | $116M | $103M | $84M | $74M |
Single-asset commercial dependency
Based on reported figures, BCRX trades at a P/S of 2.38 and a P/FCF of 6.37, suggesting that the market is pricing in significant skepticism regarding the long-term sustainability of Orladeyo's growth trajectory compared to broader biotech peers with more diversified revenue streams.
The current valuation multiples appear to discount the company's recent inflection toward positive operating income, likely due to concerns over the sustainability of orphan drug pricing. Investors should monitor whether these low multiples represent a value opportunity or a structural recognition of the company's limited pipeline diversification.
As reported in financial statements, the company's ROIC has fluctuated wildly from a negative 11.8% in 2023Q4 to a peak of 81.4% in 2025Q4, indicating that BioCryst has yet to establish a stable compounding mechanism for its invested capital base.
The extreme variance in returns suggests that profitability is currently driven more by lumpy revenue recognition and non-recurring items than by consistent operational efficiency. This volatility warrants further investigation into whether the company can maintain positive returns as it scales its commercial infrastructure.
According to recent SEC filings, the company's cash conversion cycle has shown extreme instability, swinging from a high of 981 days in 2024Q1 to a negative 28 days in 2025Q4, highlighting significant friction in managing receivables and inventory for its specialized orphan drug portfolio.
The erratic nature of the CCC suggests that BioCryst faces structural challenges in aligning its supply chain with the timing of government contracts and international launches. Such inefficiencies may continue to pressure liquidity until the company achieves a more predictable, recurring revenue mix.
Based on the latest quarterly data, the current ratio of 1.91 indicates that while BioCryst maintains a basic level of short-term solvency, its liquidity position remains vulnerable to the lumpy cash outflows observed in recent periods, such as the $489.5 million acquisition-related expenditure.
The company's reliance on external financing to bridge operational gaps suggests that its liquidity position is not yet self-sustaining. Market participants should monitor the cash runway closely, as any further clinical setbacks could necessitate dilutive capital raises to maintain operations.
The P/E ratio is the most commonly misapplied metric for BioCryst, as it fails to account for the massive distortions caused by non-cash stock-based compensation and the lumpy nature of government contract revenue that frequently swings the company between GAAP profitability and deep losses.
Investors should instead focus on cash-based metrics like EV/EBITDA or adjusted free cash flow to better gauge the underlying earning power of the Orladeyo franchise. Relying on P/E in this context may lead to a fundamental misunderstanding of the company's actual cash-generating capacity.
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BCRX stock.
BioCryst Pharmaceuticals, Inc.'s current P/E ratio is 8.4x. The historical average is 6.4x. This places it at the 100th percentile of its historical range.
BioCryst Pharmaceuticals, Inc.'s current EV/EBITDA is 7.4x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 6.1x.
Based on historical data, BioCryst Pharmaceuticals, Inc. is trading at a P/E of 8.4x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
BioCryst Pharmaceuticals, Inc. has 97.8% gross margin and 39.0% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
BioCryst Pharmaceuticals, Inc.'s Debt/EBITDA ratio is 1.4x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.